After speaking with Zogenix management on the heels of the company's announcement of a delay in the PDUFA date for Fintepla for Dravet syndrome, SVB Leerink analyst Marc Goodman said he remains "very confident" that the drug will get approved. Management said that the additional data requested by the FDA are existing data, so they do not have to do any additional studies. They added that the data requested is related to efficacy, not safety, which Goodman also views as good news. He maintains an Outperform rating on Zogenix shares, which are down about 19% to $21.18 in early trading.

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link